Skip to main content

Table 2 Univariate and multivariate analysis for CKD progression and accelerated eGFR decline in patients with type 2 diabetes

From: Addition of nonalbumin proteinuria to albuminuria improves prediction of type 2 diabetic nephropathy progression

 

Univariate analysis

Multivariate analysisa

HR

95% CI

P value

HR

95% CI

P value

CKD progression

 Model 1

  ACR < 30

1

Ref.

 

1

Ref.

 

  ACR ≥ 30

4.22

1.76–10.11

0.001

3.43

1.34–8.76

0.010

 Model 2

  NAPCR < 120

1

Ref.

 

1

Ref.

 

  NAPCR ≥ 120

7.59

2.60–22.15

<0.001

6.84

2.25–20.85

0.001

 Model 3

  ACR < 30; NAPCR < 120

1

Ref.

 

1

Ref.

 

  ACR < 30; NAPCR ≥ 120

18.88

2.27–157.05

0.007

21.82

2.57–185.62

0.005

  ACR ≥ 30; NAPCR < 120

11.90

1.23–114.79

0.032

11.62

1.19–113.97

0.035

  ACR ≥ 30; NAPCR ≥ 120

27.27

3.60–206.66

0.001

21.40

2.70–169.78

0.004

Accelerated eGFR decline

 Model 1

  ACR < 30

1

Ref.

 

1

Ref.

 

  ACR ≥ 30

1.72

1.08–02.76

0.024

1.55

0.92–2.61

0.100

 Model 2

  NAPCR < 120

1

Ref.

 

1

Ref.

 

  NAPCR ≥ 120

2.01

1.25–3.24

0.004

1.95

1.16–3.26

0.011

 Model 3

  ACR < 30; NAPCR < 120

1

Ref.

 

1

Ref.

 

  ACR < 30; NAPCR ≥ 120

1.64

0.81–3.31

0.170

1.66

0.81–3.43

0.169

  ACR ≥ 30; NAPCR < 120

1.21

0.52–2.84

0.659

1.12

0.47–2.70

0.800

  ACR ≥ 30; NAPCR ≥ 120

2.39

1.36–4.17

0.002

2.28

1.21–4.29

0.011

  1. Model 1, vs. normoalbuminuria; model 2, vs. NAPCR levels below 120 mg/g; model 3, vs. normoalbuminuria and NAPCR levels below 120 mg/g
  2. aAdjusted for age, sex, duration of diabetes, SBP, LDL, HbA1c, baseline eGFR, RAS inhibitor use and lipid-lowering agent use
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us